Reta glucagon-like peptide-1 (GLP-1) receptor agonists offer a groundbreaking approach to diabetes management. These innovative therapies work by mimicking the inherent actions of GLP-1, a hormone produced by the gut in response to food. By activating GLP-1 receptors in the pancreas, these compounds increase insulin secretion and suppress glucagon

The burgeoning landscape of emerging treatments for body management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a alike therapeutic goal – improving glycemic control and promoting significant weight loss – they exhibit intriguing variations in their pharmaco